Synchron raises $200M Series D to support BCI commercialization, next-gen tech

Synchron Raises $200 Million Series D to Advance BCI Commercialization and Next-Gen Technology

Synchron announced the successful completion of a $200 million Series D funding round to push forward the commercialization of its brain-computer interface (BCI) system. Based in New York, the company will utilize this capital to speed up bringing its Stentrode BCI to market and to further develop an advanced generation of the device.

Funding and Strategic Plans

Investors and Partnerships

About Stentrode BCI

"Stentrode — which is implanted through an endovascular approach — detects motor intention from blood vessels within the brain."

Synchron emphasizes that its system uniquely accesses blood vessels to capture brain signals. The implant is positioned on the motor cortex surface via the jugular vein, enabling detection of motor commands.

Author's summary

Synchron’s $200M Series D funding fuels the launch of its innovative Stentrode BCI and the development of cutting-edge brain-computer interfaces, backed by a diversified investor base and expanded R&D efforts.

more

MassDevice MassDevice — 2025-11-07

More News